Literature DB >> 29174734

rpoB gene sequencing highlights the prevalence of an E. miricola cluster over other Elizabethkingia species among UK cystic fibrosis patients.

Dervla T D Kenna1, Alice Fuller2, Kate Martin2, Claire Perry2, Rachel Pike2, Phillipa J Burns3, Omendra Narayan3, Stuart Wilkinson3, Robert Hill2, Neil Woodford2, Julie M J Logan2, Jane F Turton2.   

Abstract

Difficulties in distinguishing species of the Elizabethkingia genus by MALDI-TOF prompted use of rpoB sequencing to investigate species distribution among 44 isolates from cystic fibrosis (CF) patients. Forty-three isolates from 38 patients formed a cluster comprising E. miricola and proposed novel species E. bruuniana sp. nov., the exception clustering with proposed species E. ursingii sp. nov., also part of this wider cluster. All 44 isolates were PCR-positive for urease gene ureG, whereas only one of 23 E. anophelis isolates from non-CF patients was positive, suggesting that this gene is largely associated with the E. miricola cluster. Antibiotic susceptibilities of 12 CF isolates revealed all were resistant to beta-lactams with the exception of piperacillin-tazobactam, and were only susceptible to minocycline and co-trimoxazole. Pulsed-field gel electrophoresis analysis revealed 4 shared strains among 17 CF patients in one pediatric clinic, but epidemiological investigations did not support patient-to-patient transmission except between one sibling pair. Crown
Copyright © 2017. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cystic fibrosis; Elizabethkingia spp.; Minimum inhibitory concentration; Prevalence; Urease

Mesh:

Substances:

Year:  2017        PMID: 29174734     DOI: 10.1016/j.diagmicrobio.2017.10.014

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  6 in total

1.  A Real-Time Multiplex PCR Assay for Detection of Elizabethkingia Species and Differentiation between Elizabethkingia anophelis and E. meningoseptica.

Authors:  Aubree J Kelly; Sandor E Karpathy; Christopher A Gulvik; Melissa L Ivey; Anne M Whitney; Melissa E Bell; Ainsley C Nicholson; Ben W Humrighouse; John R McQuiston
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

2.  In vitro activities of imipenem, vancomycin, and rifampicin against clinical Elizabethkingia species producing BlaB and GOB metallo-beta-lactamases.

Authors:  Tein-Yao Chang; Hsing-Yu Chen; Yu-Ching Chou; Yun-Hsiang Cheng; Jun-Ren Sun
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-07-27       Impact factor: 3.267

Review 3.  Epidemiology and Characteristics of Elizabethkingia spp. Infections in Southeast Asia.

Authors:  Asdren Zajmi; Jeanette Teo; Chew Chieng Yeo
Journal:  Microorganisms       Date:  2022-04-22

4.  The draft genomes of Elizabethkingia anophelis of equine origin are genetically similar to three isolates from human clinical specimens.

Authors:  William L Johnson; Akhilesh Ramachandran; Nathanial J Torres; Ainsley C Nicholson; Anne M Whitney; Melissa Bell; Aaron Villarma; Ben W Humrighouse; Mili Sheth; Scot E Dowd; John R McQuiston; John E Gustafson
Journal:  PLoS One       Date:  2018-07-19       Impact factor: 3.240

Review 5.  Elizabethkingia Infections in Humans: From Genomics to Clinics.

Authors:  Jiun-Nong Lin; Chung-Hsu Lai; Chih-Hui Yang; Yi-Han Huang
Journal:  Microorganisms       Date:  2019-08-28

6.  Molecular Characteristics and Antimicrobial Susceptibility Profiles of Elizabethkingia Clinical Isolates in Shanghai, China.

Authors:  Leilei Wang; Xuefei Zhang; Dan Li; Fupin Hu; Minggui Wang; Qinglan Guo; Fan Yang
Journal:  Infect Drug Resist       Date:  2020-01-29       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.